Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor–like factor 2 (CRLF2), and other tumors with constitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigert, Oliver, Lane, Andrew A., Bird, Liat, Kopp, Nadja, Chapuy, Bjoern, van Bodegom, Diederik, Toms, Angela V., Marubayashi, Sachie, Christie, Amanda L., McKeown, Michael, Paranal, Ronald M., Bradner, James E., Yoda, Akinori, Gaul, Christoph, Vangrevelinghe, Eric, Romanet, Vincent, Murakami, Masato, Tiedt, Ralph, Ebel, Nicolas, Evrot, Emeline, De Pover, Alain, Régnier, Catherine H., Erdmann, Dirk, Hofmann, Francesco, Eck, Michael J., Sallan, Stephen E., Levine, Ross L., Kung, Andrew L., Baffert, Fabienne, Radimerski, Thomas, Weinstock, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280877/
https://www.ncbi.nlm.nih.gov/pubmed/22271575
http://dx.doi.org/10.1084/jem.20111694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280877/
https://www.ncbi.nlm.nih.gov/pubmed/22271575
http://dx.doi.org/10.1084/jem.20111694

Ejemplares similares